Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company PIC

Hansoh Pharmaceutical Posts 35.8% Profit Growth in 1H 2026 as Innovative Drugs Reach 85% of Revenue; First Newco Out‑Licensing Deal Marked

Fineline Cube Aug 27, 2026
Company PIC

HitGen Posts 52% Revenue Growth in 1H 2026 as DEL Segment Surges 62% and Recurring Profit Jumps 43%

Fineline Cube Aug 27, 2026
Company PIC

Junshi Biosciences Achieves First‑Ever Semiannual Profitability as Toripalimab Sales Surge 36%

Fineline Cube Aug 27, 2026
Company Drug PIC

FDA Approves Revolution Medicines’ Rasonque (daraxonrasib), an Oral Multi‑Selective RAS(ON) Inhibitor, for Metastatic Pancreatic Cancer

Fineline Cube Aug 27, 2026
Company Drug PIC

NMPA Approves Novartis’ Pluvicto Plus ARPI for PSMA‑Positive mHSPC in China, Advancing Radioligand Therapy to Earlier Prostate Cancer

Fineline Cube Aug 26, 2026
Company PIC

Hansoh Pharmaceutical Posts 35.8% Profit Growth in 1H 2026 as Innovative Drugs Reach 85% of Revenue; First Newco Out‑Licensing Deal Marked

Fineline Cube Aug 27, 2026
Company PIC

Hansoh Pharmaceutical Posts 35.8% Profit Growth in 1H 2026 as Innovative Drugs Reach 85% of Revenue; First Newco Out‑Licensing Deal Marked

Fineline Cube Aug 27, 2026
Company PIC

HitGen Posts 52% Revenue Growth in 1H 2026 as DEL Segment Surges 62% and Recurring Profit Jumps 43%

Fineline Cube Aug 27, 2026
Company Drug

Tasly Pharmaceuticals Gets NMPA Approval for B1344 Clinical Study in NASH

Fineline Cube Sep 28, 2023

Tasly Pharmaceuticals (SHA: 600535), a China-based pharmaceutical company, has announced that it has received approval...

Company Drug

ImmuneOnco Initiates Phase I Trial for CD24-Targeted Monoclonal Antibody IMM47

Fineline Cube Sep 28, 2023

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) has announced the first patient dosing in a...

Company Deals

MitrAssist Lifesciences Secures $100 Million in Series C Financing for Cardiovascular Devices

Fineline Cube Sep 28, 2023

MitrAssist Lifesciences Ltd, a Shanghai-based innovator in cardiovascular device manufacturing, has reportedly raised nearly USD...

Company Drug

Mabwell Bioscience Initiates Phase Ib/II Study for Nectin-4 Targeting ADC 9MW2821

Fineline Cube Sep 28, 2023

Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a China-based biopharmaceutical company, has announced the first...

Company Drug

LEO Pharma Initiates Phase III Clinical Trial for Delgocitinib in China

Fineline Cube Sep 28, 2023

Denmark-based LEO Pharma A/S has announced the commencement of a China Phase III clinical study...

Policy / Regulatory

Beijing Insurance Bureau Launches Pilot to Boost Access to NRDL Drugs

Fineline Cube Sep 28, 2023

The Beijing Municipal Medical Insurance Bureau has announced the initiation of pilot work aimed at...

Policy / Regulatory

Beijing-Tianjin-Hebei Region Initiates Drug VBP with 37 Medicines, Including Biologics

Fineline Cube Sep 28, 2023

The Beijing Municipal Medical Insurance Bureau has issued a notification to commence the drug volume-based...

Company Deals

Regeneron Pharmaceuticals Acquires Decibel Therapeutics to Advance Hearing Loss Treatments

Fineline Cube Sep 27, 2023

Regeneron Pharmaceuticals (NASDAQ: REGN) has completed the acquisition of Decibel Therapeutics, a developer of gene...

Company Deals

Novo Nordisk Partners with Valo Health to Develop Cardiometabolic Disease Therapies

Fineline Cube Sep 27, 2023

Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) has announced a strategic partnership with US company...

Company Drug

Coherus Biosciences Awaits FDA Decision on Toripalimab with Year-End Approval Forecast

Fineline Cube Sep 27, 2023

Coherus Biosciences Inc., (NASDAQ: CHRS), a US-based biotechnology company, has provided an update on the...

Company Drug

Cutia Therapeutics Files for Market Approval of CU-10201 with NMPA for Acne Treatment

Fineline Cube Sep 27, 2023

Cutia Therapeutics (HKG: 2487), a developer focused on dermatology therapies, has announced the submission of...

Drug

United Laboratories Receives FDA Approval for Clinical Study of UBT251 for Obesity Treatment

Fineline Cube Sep 27, 2023

United Laboratories International Holdings Ltd (HKG: 3933), a Hong Kong-based pharmaceutical company, has announced that...

Company Drug

BioTroy Therapeutics Receives US FDA IND Approval for Anti-Tumor Drug BT02

Fineline Cube Sep 27, 2023

BioTroy Therapeutics, a Shanghai-based developer of cancer immunotherapies, has announced the receipt of Investigational New...

Company Drug

Sichuan Kelun-Biotech’s KL-A167 and SKB264 Gain Tacit Clinical Trial Approval in China

Fineline Cube Sep 27, 2023

The Center for Drug Evaluation (CDE) website has indicated that Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd...

Company

Sino Biopharmaceutical Reports H1 2023 Revenue Growth, Focus on Innovative Drugs

Fineline Cube Sep 27, 2023

Sino Biopharmaceutical Ltd (HKG: 1177), a leading China-based biotech company, has released its financial report...

Company Deals

Suzhou Novoprotein and Shanghai Model Organisms Center Ink Global Partnership

Fineline Cube Sep 27, 2023

Suzhou Novoprotein Scientific Co., Ltd, (SHA: 688137) a leading provider of protein technology and application...

Company

Sihuan Pharmaceutical Reports H1 2023 Revenue Dip Amid R&D Focus

Fineline Cube Sep 27, 2023

Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has released its financial report for the first...

Company Medical Device

CIRC Unveils FuZhi 1.0 Smart Nuclear Medicine System at Chinese Medical Association Meeting

Fineline Cube Sep 27, 2023

China Isotope & Radiation Corporation (CIRC; HKG: 1763) has announced the launch of its innovative...

Policy / Regulatory

Hunchun Port Designated as Medical Materials Import Port by NMPA and GAC

Fineline Cube Sep 27, 2023

The National Medical Products Administration (NMPA) and the General Administration of Customs have jointly released...

Company

Baxter Appoints Wu Xin as China General Manager Amid Spin-Off of Kidney Care Business

Fineline Cube Sep 27, 2023

Baxter (NYSE: BAX), a leading provider of healthcare products, has announced the appointment of Wu...

Posts pagination

1 … 513 514 515 … 713

Recent updates

  • Hansoh Pharmaceutical Posts 35.8% Profit Growth in 1H 2026 as Innovative Drugs Reach 85% of Revenue; First Newco Out‑Licensing Deal Marked
  • HitGen Posts 52% Revenue Growth in 1H 2026 as DEL Segment Surges 62% and Recurring Profit Jumps 43%
  • CSPC’s PD-1/IL-15 Bispecific SYS6090 (JMT108) Granted FDA Fast Track for MSS/pMMR Metastatic Colorectal Cancer
  • Insilico Medicine Swings to Profitability as Revenue Surges 287% in 1H 2026, Rentosertib Advances to Phase 3
  • Huadong Medicine’s ROR1 ADC HDM2005 Granted FDA Fast Track Designation — First Domestic ROR1 ADC to Achieve the Status
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company PIC

Hansoh Pharmaceutical Posts 35.8% Profit Growth in 1H 2026 as Innovative Drugs Reach 85% of Revenue; First Newco Out‑Licensing Deal Marked

Company PIC

HitGen Posts 52% Revenue Growth in 1H 2026 as DEL Segment Surges 62% and Recurring Profit Jumps 43%

Company Drug

CSPC’s PD-1/IL-15 Bispecific SYS6090 (JMT108) Granted FDA Fast Track for MSS/pMMR Metastatic Colorectal Cancer

Company

Insilico Medicine Swings to Profitability as Revenue Surges 287% in 1H 2026, Rentosertib Advances to Phase 3

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2026 | Fineline Information & Technology | BlogData by Themeansar.